Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral MLN9708 with melphalan and prednisone in newly diagnosed multiple myeloma
2010-023772-71Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in multiple myeloma (MM) (2 arms), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoints: Safety, dose-limiting toxicity, and recommended phase 2 dose for twice-weekly schedule, Safety, dose-limiting toxicity, and recommended phase 2 dose for once-weekly schedule and 2 more. Started Feb 2011; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-023772-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023772-71.